Weight Loss Medications - Orlistat, Sibutramine, Appetite Suppressants
Obesity affects approximately 650 million adults worldwide according to WHO — more than 13% of the global adult population — and rates continue to rise across all regions. Obesity is not merely cosmetic: it substantially increases risk of type 2 diabetes, cardiovascular disease, several cancers, joint disease, sleep apnea, fatty liver disease, infertility, and depression, and reduces life expectancy by an average of 6-7 years for severely obese individuals. Effective weight management improves all these outcomes when sustained.
Modern obesity care emphasises comprehensive lifestyle intervention (nutrition, physical activity, behavioural support, sleep, stress management) as foundation, with pharmacotherapy and bariatric surgery as adjuncts for moderate-to-severe cases. The pharmacological landscape has transformed dramatically with GLP-1 receptor agonists (semaglutide / Ozempic, Wegovy, tirzepatide / Mounjaro, Zepbound) producing 15-20% weight loss in clinical trials — previously only achievable through surgery. Older agents like orlistat (Xenical, Orligal, Orlijohn, Slimtop), the older sympathomimetic phentermine (Phenamax), and the naltrexone-bupropion combination (Lodonak BP) remain important options.
This catalogue includes several agents that are historically significant but now withdrawn or restricted in most markets — including rimonabant (Acomplia), withdrawn worldwide in 2008 because of psychiatric side effects, and sibutramine (Reductil), withdrawn from most markets in 2010 because of cardiovascular events. These remain listed for historical and informational completeness; they are not currently recommended for weight management. Modern first-line therapy uses GLP-1 agonists, orlistat, or naltrexone-bupropion combination with appropriate clinical supervision.
💊 Conditions This Category Treats
Obesity (BMI 30+) and overweight with comorbidities (BMI 27+ with diabetes, hypertension, dyslipidaemia, sleep apnea, fatty liver) are the primary indications for pharmacotherapy. Treatment is more effective when initiated early before significant complications develop, and when integrated with structured lifestyle programmes including nutrition counselling and physical activity guidance. Bariatric surgery remains the most effective intervention for severe obesity (BMI 40+) or BMI 35+ with serious comorbidities, but the new GLP-1 receptor agonists are increasingly approaching surgical efficacy.
Beyond pure weight management, this catalogue supports type 2 diabetes management (where weight loss can lead to remission in early disease — DiRECT trial showed 46% remission rate with intensive intervention), fatty liver disease (where 7-10% weight loss substantially improves), polycystic ovary syndrome (weight loss restores ovulation and improves metabolic features), severe obesity-related sleep apnea, and obesity hypoventilation syndrome.
Approaches vary by mechanism. Orlistat-based products (Xenical, Orligal, Orlijohn, Slimtop) reduce fat absorption peripherally; Lodonak BP (naltrexone + bupropion) works centrally on reward and appetite; Phenamax (phentermine) reduces appetite through sympathomimetic effect (short-term use); Obestat represents historical sibutramine alternative. The pharmacology landscape has shifted decisively toward GLP-1 agonists since 2021, with semaglutide and tirzepatide now representing standard of care for moderate-to-severe obesity where access and cost allow.
💊 How Modern Weight Loss Treatment Works
Orlistat (Xenical, Orligal, Orlijohn, Slimtop) is a gastrointestinal lipase inhibitor that reduces dietary fat absorption by approximately 30%. Result: typically 3-5% weight loss compared to placebo over 1 year; significantly more in highly adherent patients on reduced-fat diet. The unabsorbed fat passes through the GI tract, causing the characteristic side effects (oily stools, faecal urgency, flatulence) particularly with high-fat meals — this provides built-in feedback for dietary change. Reduced absorption also affects fat-soluble vitamins (A, D, E, K) — supplement separately from orlistat dose.
Naltrexone-bupropion combination (Lodonak BP) uses two well-established medications targeting reward and appetite pathways. Bupropion (norepinephrine-dopamine reuptake inhibitor) activates POMC neurons in the hypothalamic appetite centre; naltrexone (opioid receptor antagonist) blocks the negative feedback that normally limits POMC activation. Result: sustained appetite reduction. Average weight loss is 5-9% over 1 year in clinical trials, alongside diet and exercise. Suitable for patients with food-craving patterns; useful in combination with bupropion's other benefits (mood, smoking cessation).
Phentermine (Phenamax) is a sympathomimetic that releases noradrenaline in the hypothalamus, suppressing appetite. Effective for short-term weight loss (12 weeks typically in US prescribing); produces 3-7% weight loss. Side effects include insomnia, dry mouth, palpitations, anxiety, and elevated blood pressure. Contraindicated in cardiovascular disease, uncontrolled hypertension, hyperthyroidism, history of substance abuse, and MAOI use. Historical agents like sibutramine (Reductil) and rimonabant (Acomplia) had significant cardiovascular and psychiatric adverse effects respectively, leading to withdrawal from most regulatory markets; included in catalogue for historical reference only. Modern guidelines emphasise GLP-1 receptor agonists as first-line for moderate-to-severe obesity where access and cost allow.
💊 Drug Classes in This Category
| Class | Best For | Examples |
|---|---|---|
| Lipase inhibitors | Long-term weight management; modest weight loss with dietary fat avoidance | Xenical (orlistat), Orligal, Orlijohn, Slimtop |
| Naltrexone + bupropion combination | Patients with food cravings, comorbid mild depression, smoking cessation interest | Lodonak BP |
| Sympathomimetic (appetite suppressant) | Short-term (12 weeks) weight loss in appropriate candidates | Phenamax |
| Historical / restricted agents | Withdrawn in most markets — not currently recommended | Acomplia (rimonabant), Sibutramine (Reductil), Obestat |
✅ How to Choose
- 🍲 BMI 27-30 with mild lifestyle change ambition → Xenical / Orligal (orlistat) 120 mg three times daily with meals; commit to reduced-fat diet and physical activity.
- 🤯 Strong food cravings or emotional eating pattern → Lodonak BP (naltrexone + bupropion); combines appetite reduction with mood and motivation effects.
- 🫀 Significant cardiovascular comorbidities (untreated hypertension, recent MI, severe arrhythmia) → avoid stimulant appetite suppressants; consider orlistat (no cardiovascular effects) or specialist consultation for GLP-1 agonist access.
- 🏃 Athletes or those seeking modest body composition improvements without significant disease → lifestyle intervention without pharmacotherapy is typically the appropriate path.
- 🤰 Pregnancy or planning pregnancy → all weight loss medications are contraindicated; focus on healthy eating without significant calorie restriction.
- 🪨 Type 2 diabetes with obesity → metformin from Diabetes category as foundation; specialist input for GLP-1 agonists or SGLT2 inhibitors which support weight loss as bonus.
❓ Frequently Asked Questions about Weight Loss
How much weight can I expect to lose with these medications?
Realistic expectations: Orlistat 3-5%, Lodonak BP 5-9%, Phenamax 3-7% over 1 year alongside diet and exercise. Modern GLP-1 agonists (semaglutide, tirzepatide) achieve 15-20% — comparable to older bariatric surgery results. Without behavioural support and lifestyle change, results are substantially less.
What are orlistat side effects?
Oily spotting, oily/loose stools, faecal urgency, flatulence with discharge, abdominal cramping. These are dose-related to dietary fat intake — high-fat meals cause worse symptoms. This effectively trains low-fat eating. Side effects diminish over weeks as fat intake decreases. Supplement fat-soluble vitamins (A, D, E, K) at separate times from orlistat doses.
Can I take weight loss medications if I am breastfeeding?
No. Most weight loss medications are not recommended during breastfeeding. Focus on healthy eating and gradual return to physical activity. Postpartum weight loss often takes 6-12 months and is more important than rapid intervention.
What about herbal weight loss supplements?
The herbal weight loss market is largely unregulated, and most products lack rigorous evidence. Some contain undisclosed pharmaceutical ingredients that have caused serious adverse events. Caffeine and green tea extract have modest evidence for small weight loss. Buyer beware — stick to evidence-based approaches.
Will I regain weight after stopping medication?
Often yes — obesity is a chronic condition. Stopping medication without sustained lifestyle change typically results in gradual weight regain to pre-treatment levels within 1-2 years. Long-term medication may be appropriate for chronic obesity management, similar to long-term medication for hypertension or diabetes.
When should I consider bariatric surgery?
Consider for BMI 40+, or BMI 35+ with serious comorbidities (severe diabetes, severe obstructive sleep apnea, debilitating joint disease) when comprehensive lifestyle and pharmacotherapy have been insufficient. Modern bariatric surgery (sleeve gastrectomy, Roux-en-Y bypass) produces sustained 25-30% weight loss with major improvements in metabolic and cardiovascular health. Specialist evaluation required.
🩺 When to See a Healthcare Provider
Comprehensive obesity assessment includes BMI, waist circumference, blood pressure, lipid profile, HbA1c, liver function, sleep history, mood assessment, eating patterns, physical activity history, and motivation. Identify and address secondary causes of weight gain (hypothyroidism, Cushing syndrome, polycystic ovary syndrome, medication side effects from antipsychotics, steroids, certain antidepressants, antiepileptics).
Long-term obesity management is best supported by multidisciplinary teams including primary care, dietitian, behavioural therapist, and where applicable bariatric specialist. Mental health support is particularly important — obesity is associated with depression, eating disorders, and emotional eating patterns. Always inform every prescriber about weight loss medications — interactions with antidepressants, mood stabilisers, and cardiovascular drugs can be important.